Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

**AR1001** is a medicine being studied to help people with early Alzheimer's Disease (AD), a condition that affects memory and thinking. This study is *phase 3*, meaning it is one of the last steps before the medicine can be approved for general use. It is a **double-blind, randomized, placebo-controlled trial**, which means neither the doctors nor the participants know who is getting the real medicine or a fake one (placebo). The study is looking to see if AR1001 is safe and works well. People aged 55-90 with mild memory issues might join if they meet certain conditions. During the study, participants will need a caregiver or partner to help them and attend visits. Some risks include potential side effects, and participants must not have certain other health issues. The study lasts for some time, and participants might be compensated for their time and effort.

• **Duration**: Participants will be involved for an extended period.
• **Visits**: Regular clinic visits are required, with a caregiver's help.
• **Compensation**: Participants may receive compensation for participation.